GSK’s Drug for COPD Gets FDA Nod

by Kathy Jones on  May 13, 2013 at 11:50 PM Drug News
RSS Email Print This Page Comment
GlaxoSmithKline announced that their drug, Breo Ellipta, has been approved by the US Food and Drug Administration for use in treating chronic obstructive pulmonary disease (COPD).
 GSK’s Drug for COPD Gets FDA Nod
GSK’s Drug for COPD Gets FDA Nod
Advertisement

The drug has been developed in collaboration with Theravance Inc with analysts predicting that it could generate annual sales of over $4 billion worldwide.

Advertisement
Both the companies revealed that the drug will be made available in the third quarter of this year and Theravance owes a $30 million milestone payment to Glaxo following the FDA approval.

Stating that the approval will provide different options for treating COPD, the director of FDA Office of Drug Evaluation II, Curtis Rosebraugh said, "COPD is a serious disease that makes breathing difficult. The availability of new long-term maintenance medications provides additional treatment options for the millions of Americans who suffer with COPD".

Source: Medindia
Advertisement

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
Notify me when reply is posted
I agree to the terms and conditions

More News on:

Drug Toxicity Signature Drug Toxicity Pneumoconiosis Pulmonary Arterial Hypertension Chronic Obstructive Pulmonary Disease Emphysema Pneumonectomy Chronic Bronchitis 
Advertisement

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Advertisement

Advertisement
Advertisement

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive